• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NorthView Acquisition Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/25/25 8:15:32 PM ET
    $NVAC
    Medical/Dental Instruments
    Health Care
    Get the next $NVAC alert in real time by email
    false --12-31 0001859807 0001859807 2025-03-21 2025-03-21 0001859807 NVAC:SharesOfCommonStockParValue0.0001PerShareMember 2025-03-21 2025-03-21 0001859807 NVAC:RightsEachEntitlingHolderToReceiveOnetenthOfOneShareOfCommonStockMember 2025-03-21 2025-03-21 0001859807 NVAC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerWholeShareMember 2025-03-21 2025-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 21, 2025

     

    NORTHVIEW ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41177   86-3437271
    (State or other jurisdiction of
    incorporation or organization)
      (Commission File Number)   (IRS Employer
    Identification Number)

     

    207 WEST 25TH ST., 9TH FLOOR

    NEW YORK, NY 10001

    (Address of principal executive offices and zip code)

     

    (212) 494-9022

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Shares of common stock, par value $0.0001 per share   NVAC   The NASDAQ Stock Market LLC
    Rights, each entitling the holder to receive one-tenth of one share of common stock   NVACR   The NASDAQ Stock Market LLC
    Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per whole share   NVACW   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company  ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

     

     

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws.

     

    The information included in Item 5.07 of this Current Report on Form 8-K is incorporated by reference in this Item 5.03 to the extent required herein.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    As previously announced, on March 18, 2025, NorthView Acquisition Corporation (the “Company”) adjourned its Special Meeting of Stockholders (the “Meeting”). On March 21, 2025, the Company reconvened the Meeting, at which the Company’s stockholder of record voted on the proposals set forth below, each of which is described in detail in the proxy statement filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2025, which was first mailed by the Company to its stockholders on or about September 12, 2024. The Company’s definitive proxy statement was supplemented with the additional solicitation material filed with the SEC on March 18, 2025.

     

    As of February 21, 2025, the record date for the Meeting, there were 5,881,269shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company issued and outstanding and entitled to vote at the Meeting. A total of 5,661,515 shares of the Common Stock, representing approximately 92.2% of the issued and outstanding shares of the Common Stock, were present in person by virtual attendance or represented by proxy at the Meeting, constituting a quorum for the Meeting. The final voting results for each proposal submitted to the stockholders of record of the Company at the Meeting are included below.

     

    Each of the proposals described below was approved by the Company’s stockholders of record. In connection with the proposals, 532,958 shares of the Company’s common stock were redeemed (the “Redemption”), with 5,348,311 shares of Common Stock remaining outstanding after the Redemption; 154,561 shares of Common Stock remaining outstanding after the Redemption are shares issued in connection with our initial public offering (the “Public Shares”). The Company initiated the contribution of $30,000 to the Company’s trust account at Continental Stock and Transfer on or about March 21, 2025. Our public stockholders will continue to have the opportunity to redeem all or a portion of their Public Shares upon the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount on deposit in the trust account as of two business days prior to the vote to approve the consummation of our initial business combination, including interest, divided by the number of then outstanding Public Shares, subject to the limitations described herein.

     

    If we are unable to complete an initial business combination on or before June 22, 2025, (unless the stockholders approve a further amendment to the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination), we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

     

    1

     

     

    Set forth below are the final voting results for the proposals:

     

    Proposal 1:

     

    A proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares of the Company’s common stock issued in the Company’s initial public offering, from March 22, 2025 until as late as June 22, 2025.

     

    For   Against   Abstentions
    5,661,016   499   0

     

    Proposal 2:

     

    A proposal to approve the amendment to the Investment Management Trust Agreement, dated December 20, 2021, by and between the Company and Continental Stock Transfer & Company, to authorize the extension subject to Proposal 1 above and its implementation by the Company.

     

    For   Against   Abstentions
    5,661,016   499   0

     

    Proposal 3:

     

    A proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that would prevent the Company from redeeming public shares that would cause the Company to have net tangible assets of less than $5,000,001.

     

    For   Against   Abstentions
    5,661,016   499   0

     

    Proposal 4:

     

    A proposal to approve the adjournment of the Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the forgoing proposals.

     

    For   Against   Abstentions
    5,661,016   499   0

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Amendment to Amended and Restated Certificate of Incorporation of NorthView Acquisition Corporation, dated March 21, 2025
    10.1   Form of Amendment to the Investment Management Trust Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NORTHVIEW ACQUISITION CORP.
         
    Date: March 25, 2025 By: /s/ Fred Knechtel 
      Name:  Fred Knechtel 
      Title: Chief Financial Officer

     

     

    3

     

     

     

    Get the next $NVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Failure to Complete Initial Business Combination

      New York, NY, Dec. 26, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that (i) the Staff has determined that the Company's securities will be delisted from The Nasdaq Stock Market; (ii) trading of the Company's Common Stock, Rights, and Warrants will be suspended at the opening of business on December 27, 2024; and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing on The Nasdaq Stock Market. Pursuant to

      12/26/24 4:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Quarterly Report on Form 10-Q

      New York, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the

      12/11/24 6:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules

      New York, NY, Sept. 13, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") granting the Company an exception to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). Pursuant to the terms of the exception, the Company must file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 on or prior to October 14, 2024. If the Company does not satisfy the terms of the exception, the

      9/13/24 4:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care

    $NVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NorthView Acquisition Corporation

      SC 13G - NorthView Acquisition Corp (0001859807) (Subject)

      3/27/24 6:05:55 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NorthView Acquisition Corporation (Amendment)

      SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)

      2/22/24 9:05:41 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NorthView Acquisition Corporation (Amendment)

      SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)

      2/14/24 4:53:53 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care

    $NVAC
    SEC Filings

    See more
    • SEC Form 25-NSE filed by NorthView Acquisition Corporation

      25-NSE - NorthView Acquisition Corp (0001859807) (Subject)

      5/22/25 3:34:04 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by NorthView Acquisition Corporation

      424B3 - NorthView Acquisition Corp (0001859807) (Filer)

      5/15/25 5:24:53 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NorthView Acquisition Corporation

      EFFECT - NorthView Acquisition Corp (0001859807) (Filer)

      5/15/25 12:15:07 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care